Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

107.90 -1.85 (-1.69%)
Streaming Delayed Price Updated: 12:47 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Unveiling 14 Analyst Insights On Axsome Therapeutics
Via Benzinga
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.
From Axsome Therapeutics, Inc.
Via GlobeNewswire
New Study Reveals How Classical Music Could Revolutionize Depression Care
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... 
Via PressReach
Exposures Product Safety
A Glimpse Into The Expert Outlook On Axsome Therapeutics Through 9 Analysts
Via Benzinga
Decoding 9 Analyst Evaluations For Axsome Therapeutics
Via Benzinga
Should You Buy This Sinking Stock on the Dip?
The biotech isn't having the best year. 
Via The Motley Fool
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Lithia Motors To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript
AXSM earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Axsome Therapeutics Stock Is Sinking Today
Investors were unhappy with Axsome's worse-than-expected Q2 loss. 
Via The Motley Fool
15 Analysts Assess Axsome Therapeutics: What You Need To Know
Via Benzinga
Axsome Plunges On Wide Losses, But Its Biggest Moneymaker Tacks On 135% Growth
The company makes treatments for depression and excessive daytime sleepiness. 
Via Investor's Business Daily
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
From FN Media Group LLC
Via GlobeNewswire
Jim Cramer Calls Axsome A 'Double Or Nothing Stock,' Says SAP Is 'Incredible'
Jim Cramer discusses Torm, Trane, Sap and Axsome Therapeutics on CNBC's "Mad Money Lightning Round." 
Via Benzinga
7 Biotech Stocks to Keep on Your Clinical Radar
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
Via InvestorPlace
Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong Future
Needham initiated coverage on Axsome Therapeutics, highlighting its diverse CNS portfolio. The analyst predicts an 8-10x risk-adjusted topline growth in five years, driven by marketed drugs Auvelity... 
Via Benzinga
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
These innovative drugmakers are hard to ignore. 
Via The Motley Fool
Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5
From Axsome Therapeutics, Inc.
Via GlobeNewswire
The 3 Best Biotech Stocks to Buy in July 2024
For investors looking for promising biotech investments should explore the best biotech stocks to watch in July 2024. 
Via InvestorPlace
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise. 
Via InvestorPlace
Why Axsome Therapeutics Stock Is Sinking Today
A short-seller report is causing a sell-off of the biotech stock. 
Via The Motley Fool
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
Data on solriamfetol featured in two oral plenary sessions 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Hello Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.